Reversal of Ketosis in Type 1 Diabetes Is Not Adversely Affected by SGLT2 Inhibitor Therapy
Siebel S, Galderisi A, Patel NS, Carria LR, Tamborlane WV, Sherr JL. Reversal of Ketosis in Type 1 Diabetes Is Not Adversely Affected by SGLT2 Inhibitor Therapy. Diabetes Technology & Therapeutics 2019, 21: 101-104. PMID: 30688521, PMCID: PMC6434586, DOI: 10.1089/dia.2018.0356.Peer-Reviewed Original ResearchConceptsType 1 diabetesFree fatty acidsSGLT2i useAspart insulinSGLT2 inhibitor therapyPlasma glucose levelsSodium-glucose cotransporterCanagliflozin treatmentEuglycemic DKARescue therapyBasal insulinInhibitor therapyRate of ketogenesisRescue treatmentBlunted increaseSubcutaneous injectionGlucose levelsTreatment studiesNormal increaseInsulinDiabetesTherapyKetogenesisFatty acidsTreatment